Aurinia Pharmaceuticals Inc.
NASDAQ•AUPH
CEO: Mr. Peter S. Greenleaf M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2014-09-03
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Contact Information
Market Cap
$2.03B
P/E (TTM)
7.0
24.5
Dividend Yield
--
52W High
$16.88
52W Low
$7.29
52W Range
Rank56Top 81.7%
2.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data